3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
91
Neoplasm Metastasis
11
Prostate Cancer Metastatic
4
Oligometastatic Prostate Cancer
3
Adenocarcinoma
3
Radiation Injuries
2
Prostatic Diseases
2
Prostate CA
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Urologic Diseases
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
PSA Level Greater Than 0.03
1
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphatic Metastasis
1
Intraprostatic Prostate Cancer
1
Insulin Resistance
1
Hormone Sensitive Prostate Cancer
1
Genital Diseases, Male
1
Interventions
Prednisolone
1
BID protein, human
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Abiraterone Acetate
×
Androgen Antagonists
×
Clear all
NCT06768255
2025-01-10
mCRPC
Fudan University
Phase 3
Not yet recruiting
400 enrolled